Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Animal Efficacy Rule Needs To Be Codified In Bioterror Bill – Hatch

Executive Summary

Sen. Orrin Hatch (R-Utah) is pushing for changes to the bioterrorism conference bill that would codify FDA's animal efficacy rule, he told a Food & Drug Law Institute meeting in Washington, D.C., April 15

You may also be interested in...

FDA Commissioner With Industry Background Would Be “Strong Plus” – Hatch

Industry experience should be considered an advantage for potential commissioner candidates in light of the importance of bioterrorism preparedness, Sen. Orrin Hatch (R-Utah) maintained April 16 at the Food & Drug Law Institute meeting in Washington, D.C

Bioterrorism Antitrust Relief Is One Of Last Major Obstacles To Consensus Bill

Antitrust exemptions for pharmaceutical companies who produce bioterrorism countermeasures is one of the last significant obstacles to moving an anti-bioterrorism authorization bill this year

PDUFA III: Bioterrorism Conference May Be Path To Clean Bill, Tauzin Says

The House/Senate bioterrorism conference bill may provide a vehicle for fast-track consideration of PDUFA III

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts